Современные возможности химиотерапии трижды негативного рака молочной железы (обзор литературы)
- Авторы: Секундова М.А.1,2, Сдвижков А.М.1,2, Борисов В.И.3
-
Учреждения:
- ГБУЗ Онкологический клинический диспансер №1 Департамента здравоохранения г. Москвы
- ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
- ГБУЗ Онкологический клинический диспансер №1 Департамента здравоохранения г.Москвы
- Выпуск: Том 16, № 1 (2014)
- Страницы: 7-12
- Раздел: Статьи
- URL: https://journals.rcsi.science/1815-1434/article/view/26923
- ID: 26923
Цитировать
Полный текст
Аннотация
Ключевые слова
Полный текст
Открыть статью на сайте журналаОб авторах
Мария Александровна Секундова
ГБУЗ Онкологический клинический диспансер №1 Департамента здравоохранения г. Москвы; ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
Email: masek84@mail.ru
аспирант каф. общей хирургии лечебного факультета ГБОУ ВПО МГМСУ, онколог отд. по профилактике и ранней диагностике онкологических заболеваний ГБУЗ ОКД №1 ДЗ г.Москвы
Александр Михайлович Сдвижков
ГБУЗ Онкологический клинический диспансер №1 Департамента здравоохранения г. Москвы; ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава Россиид-р мед. наук, проф. каф. общей хирургии лечебного факультета ГБОУ ВПО МГМСУ, глав. врач ГБУЗ ОКД №1 ДЗ г.Москвы
Василий Иванович Борисов
ГБУЗ Онкологический клинический диспансер №1 Департамента здравоохранения г.Москвыд-р мед. наук, проф., зам. глав. врача по химиотерапии опухолей ГБУЗ ОКД №1 ДЗ г.Москвы
Список литературы
- Божок А.А., Семиглазов В.Ф., Семиглазов В.В. Факторы прогноза при раке молочной железы. Соврем. онкология. 2005; 7 (1): 4.
- Чиссов В.И., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 году. М.: ФГУ «МНИОИ им. П.А.Герцена» Минздравсоцразвития России, 2012.
- Blichert-Toft M, Rose C, Andersen J.A et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life - table analysis. Danish Breast Cancer Cooperative Group. J Natl Cancer Inst. Monogr 1992; р. 19-25.
- Rakha E.A, Reis-Filho J.S, Ellis I.O. Basal - like breast cancer: a critical review. J Clin Oncol 2008; 26: 2568-81.
- Tang P, Skinner K.A, Hicks D.G. Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? Diagn Mol Pathol 2009; 18: 125-32.
- Поддубная И.В., Карселадзе А.И., Кулевич Е.Е. Морфология тройного негативного рака молочной железы. Архив патологии. 2010; 72 (2): 8-12.
- Поддубная И.В. Клиническая характеристика тройного негативного рака молочной железы. Вестн. РОНЦ им. Н.Н.Блохина РАМН. 2010; 22 (1): 71-6.
- Lin N.U, Vanderplas A, Hughes M.E et al. Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). J Clin Oncol 2009; 27 (Abstr 543).
- Lehmann B.D, Bauer J.A, Chen X et al. Identification of human triple - negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-67.
- Манзюк Л.В., Артамонова Е.В. Таксотер в химиотерапии рака молочной железы. Независимое издание для практикующих врачей. Онкология. 2006; 24: 12-6.
- Химиотерапия при метастатическом раке молочной железы. Маммология. Хирургия молочной железы. http://mammalogy.eurodoctor.ru/chemotherapybreastcancer
- Частота встречаемости рака молочной железы. http://www.panaceya. com.ua/med/ article/view/92a460d6cb845 eedb2214cd8 b296c859
- Семиглазов В.Ф., Дашян Г.А., Семиглазов В.В. и др. Лечение «трижды негативного» рака молочной железы. Фарматека. 2009; 18: 14-7.
- Стенина М., Фролова М., Скрыпникова М. Базальноподобный (тройной негативный) рак молочной железы: молекулярные особенности, течение и возможные терапевтические подходы. Врач. 2010; 3: 24-8.
- Voduc K.D, Cheang M.C, Tyldesley S et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010; 28: 1684-91.
- Carey L, Dees E, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-34.
- Liedtke C, Mazouni C, Hess K.R et al. Response to neoadjuvant therapy and long - term survival in patients with triple - negative breast cancer. J Clin Oncol 2008; 26: 1275-81.
- Rouzier R, Perou C, Symmans W et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-85.
- Hayes D, Thor A, Dressler L et al. HER2 and response to paclitaxel in node - positive breast cancer. N Engl J Med 2007; 357: 1496-506.
- Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16 (8): 2672-85.
- Rocca A, Paradiso A, Sismondi P et al. Benefit from CMF with or without anthracyclines in relation to biologic profiles in early breast cancer. ASCO Annual Meet, June 3-7, Chicago, IL, 2011: Post 1031.
- Седаков И.Е. Химиотерапия рака молочной железы. Новости медицины и фармации. Маммология. 2009. http://www.mifua.com/archive/article/10749
- Cheang M.C.U, Voduc D, Tu D et al. The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial. ASCO Annual Meet, June 3-7, Chicago, IL, 2011: Post 1032.
- Ellis G, Green S, Russell C et al. SWOG 0012, a randomized phase III comparison of standard doxorubicin and cyclophosphamide followed by weekly paclitaxel vs weekly doxorubicin and daily oral cyclophos - phamide plus G-CSF followed by weekly paclitaxel vs neoadjuvant therapy for inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24: 12.
- Torrisi R, Balduzzi A, Ghisini R et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol 2008; 62: 667-72.
- Alvarado Miranda A, Lara Medina F.U, Arce C et al. Phase II open, single - arm trial: Cisplatin combined with paclitaxel and doxorubicin in operable or locally advanced triple - negative breast cancer. ASCO Annual Meet, June 3-7, Chicago, IL, 2011: Post 1135.
- Alba E, Chacon J.I, Lluch A et al. Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal - like breast cancer: GEICAM 2006-03-A multicenter, randomized phase II study. ASCO Annual Meet, June 3-7, Chicago, IL, 2011: Post 1015.
- Pivot X, Li R, Thomas S et al. Activity of ixabepilone in oestrogen receptor - negative and oestrogen receptor - progesteron receptor - human epidermal growth factor receptor-2-negative breast cancer. Eur J Cancer 2009; 45: 2940-6.
- Greil R, Moik M, Reitsamer R et al. Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu - negative invasive breast cancer: efficacy and safety in a phase II pilot study. Eur J Surg Oncol 2009; 35 (10): 1048-54.
- Gerber B, Eidtmann H, Rezai M et al. Neoadjuvant bevacizumab and anthracycline - taxane - based chemotherapry in 686 triple - negative primary breast cancers: Seconday endpoint analysis analysis of the Gepar- Quinto study (GBG 44). ASCO Annual Meet, June 3-7, Chicago, IL, 2011: Abstr 1006.
- Gonzalez-Angulo A.M, Green M.C, Murray J.L et al. Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor - negative breast cancer (TNBC). ASCO Annual Meet, June 3-7, Chicago, IL, 2011: Post 1016.
- Sparano J, Wang M, Martino S et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 1663-71.
- Citron M.L, Berry D.A, Cirrincione C et al. Randomized trial of dose - dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node - positive primary breast cancer: first report of intergroup Trial C9741. Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-9.
- Garber J, Richardson A, Harris L et al. Neo - adjuvant cisplatin (CDDP) in triple - negative breast cancer (BC). Presented at the 29th San Antonio Breast Cancer Symposium; December 14-17. 2006; San Antonio, Texas. Poster 3074.
- Byrski T, Huzarski T, Dent R et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2008; 115: 359-63.
- Mehta R.S, Liu C. Clinical outcome of triple - negative breast cancer with BRCA mutation in the context of dose - dense and or metronomic chemotherapy. ASCO Annual Meet June 3-7, Chicago, IL, 2011: Post 1109.
- Gluz O, Nitz U.A, Harbeck N et al. Triple - negative high - risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: Results of WSG AM-01 trial. Ann Oncol 2008; 19: 861-70.
- Yi S, Uhm J, Cho E et al. Clinical outcomes of metastatic breast cancer patients with triple - negative phenotype who received platinum - containing chemotherapy [abstr 1008]. Proc Am Soc. Clin Oncol 2008; 26: 15.
- Thomas E.S, Gomez H.L, Li R.K et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25: 5210-7.
- Hortobagyi G.N, Perez E, Vdoljak E et al. Analysis of overall survival amongpatienys with metastatic breast cancer receiving either ixabepilone plus capecitabine or capecitabine alone and review of results from two randomized phase III trials. ASCO Breast 2008.
- Rugo H.S, Thomas E.S, Lee R.K et al. Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabine has efficacy in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes. Breast Cancer Res Treat 2007; 106 (Suppl. 1): S270. Abstr 6069.
- Farmer H, Mc Cabe N, Lord C et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
- O’Shaughnessy J, Osborne C, Pippen J et al. Efficacy of BSI-201, a poly(ADP-ribose)polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple - negative breast cancer (TNBC): Results of a randomized phase II trial [abstr 3]. Proc Am Soc Clin Oncol 2009; 27: 18.
- Cotter M.B, Pierce A, Mc Gowan P.M et al. PARP1 in triplenegative breast cancer: Expression and therapeutic potential. ASCO Annual Meet June 3-7, Chicago, IL, 2011: Post 1061.
- Liu J, Fleming G.F, Tolaney S.M et al. A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triplenegative breast cancer. ASCO Annual Meet, June 3-7, Chicago, IL, 2011: Post 5028.
- Siziopikou K, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 2007; 1: 104-7.
- Carey L, Rugo H, Marcom P et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple - negative (basal - like) breast cancer [abstr 1009]. J Clin Oncol 2008; 26: 15.
- O’Shaughnessy J, Weckstein D, Vukelja S et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer [abstr 308]. Breast Cancer Res Treat 2007; 106: 32.
- Corkery B, Crown J, Clynes M et al. Epidermal growth factor receptor as a potential therapeutic target in triple - negative breast cancer. Ann Oncol 2009; 20 (5): 862-7.
- Mullooly M, Mc Gowan P.M, Sukor S.U et al. ADAMs as new therapeutic targets for triple - negative breast cancer. ASCO Annual Meet, June 3-7, Chicago, IL, 2011: Post 1062.
- Malin D, Chen Feng, Schiller C et al. Enhanced Metastasis Suppression by Targeting TRAIL Receptor 2 in a Murine Model of Triple-Negative Breast Cancer. Clin Cancer Res 2011; 17 (15): 5005-15.
- Reis Filho J.S, Tutt A.N.J. Triple negative tumors: a critical review. Histopathology 2008; 52: 108-18.
- Finn R, Dering J, Ginther C et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal - type/«triple - negative» breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105: 319-26.
- Finn R.S, Bengala C, Ibrahim N et al. Phase II trial of dasatinib in triple - negative breast cancer: results of study CA180059 [abstr]. San Antonio Breast Cancer Symposium December 12, San Antonio, Texas, 2008. Abstr a3118.
- Carey L, Winer E, Viale G et al. Triple - negative Breast Cancer: Disease Entity or Title of Convenience? Nat Rev Clin Oncol 2010; 7 (12): 683-92.
- O’Shaughnessy J, Dieras V, Glaspy J et al. Comparison of subgroup analyses of PFS from three phase III studies of Avastin in combination with chemotherapy in patients with HER2-negative metastatic breast cancer [poster 207]. SABCS, Dec 2009.
- Brufsky A, Valero V, Tiangco B et al. Impact of bevacizuma (BEV) on efficacy of second - line chemotherapy (CT) for triplenegative breast cancer (TNBC): Analysis of RIBBON-2. ASCO Annual Meet, June 3-7, Chicago, IL, 2011. Abstr 1010.
- Mayer E.L, Scheulen M.E, Beckman J et al. Combination of tivozanib (AV-951) with weekly paclitaxel for metastatic breast cancer: Results of a phase I study. ASCO Annual Meet June 3-7, Chicago, IL, 2011: Post 1092.
- Mayer I.A, Burris H, Bendel J et al. A phase Ib trial of RAD001, an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer. Presented at the 32nd Annual San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, Texas, USA.